NCT05624736 is a clinical trial of multi-parametric magnetic resonance imaging scan in Astrocytoma, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

What drugs are being tested in NCT05624736?

Interventions in NCT05624736: multi-parametric magnetic resonance imaging scan, Pathology examination.

What condition does NCT05624736 study?

NCT05624736 studies Astrocytoma, Glioblastoma Multiforme, Oligodendroglioma.

Is NCT05624736 still recruiting?

NCT05624736 is currently status unknown. Last updated 22 November 2022.

Last reviewed 2022-11-22 · How we verify

NCT05624736

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning

Status unknown Last updated 22 November 2022

What this trial tests

trial testing multi-parametric magnetic resonance imaging scan in Astrocytoma in 500 participants. Status unknown.

Timeline

20 November 2022

Primary endpoint
1 May 2023

1 May 2025

Quick facts

Lead sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	20 November 2022
Primary completion	1 May 2023
Estimated completion	1 May 2025
Sites	1 location across China

Drugs / interventions tested

multi-parametric magnetic resonance imaging scan
Pathology examination

Conditions studied

Astrocytoma — all drugs for Astrocytoma →
Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →
Oligodendroglioma — all drugs for Oligodendroglioma →

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Who can join

Adults 18 to 90, any sex, with Astrocytoma or Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a restrospective study to establish a deep learning model based on multi-parametric magnetic resonance imaging scans to predict Grade, histopathologic type and genotype of adult diffuse Glioma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Identification of intrinsic imaging subtypes using clustering analysis based on dynamic contrast-enhanced magnetic resonance imaging radiomics features for gliomas: preliminary associations with gene expression profiles.
Zhou J, Duan S, Zhu Z, Wang H, et al · · 2025 · cited 3× · PMID 40384650 · DOI 10.21037/qims-24-1459
Fully automated Res3DNet model to predict IDH mutation of gliomas from whole-brain MRI free of tumor segmentation.
Zhu Z, Liu Y, Song Y, Zhou J, et al · · 2026 · PMID 41531733 · DOI 10.1016/j.isci.2025.114373
OMT and tensor SVD-based deep learning model for segmentation and predicting genetic markers of glioma: A multicenter study.
Zhu Z, Wang H, Li T, Huang TM, et al · · 2025 · PMID 40627394 · DOI 10.1073/pnas.2500004122

Verify or expand the search:

Other recruiting trials for Astrocytoma

Currently open trials in the same condition.

NCT06989086 — FearLess in NeuroOncology · NA · recruiting
NCT06614855 — A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant G · Phase 1 · active not recruiting
NCT06797661 — Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients with Brain Lesions. · NA · recruiting
NCT06344130 — Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma · Phase 1 · recruiting
NCT05879367 — Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma · Phase 1 · recruiting

Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials

Trials by the same sponsor.

NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
NCT07403071 — Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Expe · not yet recruiting
NCT07532538 — A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions · not yet recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05624736 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Last refreshed: 22 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05624736.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing